Therapy of pancreatic adenocarcinoma;Therapie des pankreasadenokarzinoms

Medizinische Klinik

Volumn 94, Issue 11, 1999, Pages 614-625

  Böhmig, Michael ^b   Wiedenmann, Bertram ^b   Rosewicz, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Chemotherapy; Palliation; Pancreatic carcinoma; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GEMCITABINE; METHOTREXATE; MITOMYCIN; STREPTOZOCIN; TAMOXIFEN; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONSERVATIVE TREATMENT; HUMAN; PANCREAS ADENOCARCINOMA; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION;

EID: 0345476286     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03045002     Document Type: Review

References (184)

1. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996;8:654-63.
2. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol 1996;23:241-50.
3. Almoguera C, Shihabata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
4. Alter CL. Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 1996;23:229-40.
5. Andersen JR, Friis-Moller A, Hancke S, et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand J Gastroenterol 1981; 16:973-5.
6. Andersen JR, Sorenson SM, Kruse A, et al. Randomized trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989;30:1132-5.
7. Andrén-Sandberg A. Etiologic links between chronic pancreatitis and pancreatic cancer. Scand J Gastroenterol 1997;32:97-103.
8. Andrén-Sandberg A, Bäckmann PL, Andersson R. Results of adjuvant therapy in resected pancreatic cancer. Int J Pancreat 1997;21:31-8.
9. Andrén-Sandberg H, Homberg JT, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluoruracil, vincristine and CCNU. Scand J Gastroenterol 1983;18: 609-12.
10. Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high dose fluoruracil with or without N-(phosphonoacetyl)-L-aspartic-acid in patients with advanced pancreatic and colorectal cancers.J Clin Oncol 1988;6:1053-8.
11. Ardalan B, Ucar A, Reddy R, et al. Phase I trial of low-dose N-phosphonacetyl-l-aspartic acid and high dose 5-fluoruracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. Cancer 1994;74:1869-73.
12. Auerbach M, Wampler GL, Lokich JJ, et al. Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluoruracil and weekly carboplatin: A Mid-Atlantic Oncology Program study. Ann Oncol 1997;8:439-44.
13. Bakkevold KE, Arensjo B, Dahl O, et al. Adjuvant therapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater. Results of a controlled, prospective randomized multicentre study. Eur J Cancer 1993;29:698-703.
14. Bakkevold KE, Pettersen A, Arnesjo B, et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990;77:725-30.
15. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995;109:247-51.
16. Baumel H, Huguier M, Manderscheid JC, et al. Results of resection for cancer of the exocrine pancreas - a study from the French Association of Surgery. Br J Surg 1994;81:102-7.
17. Belli L, Riolo F, Romani F, et al. Pylorus preserving pancreatoduodenectomy versus Whipple procedure for adenocarcinoma of the head of the pancreas. HPB Surg 1989;1:195-200.
18. Bergman W, Watson P, DeJong J, et al. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990;61:932-6.
19. Bornman PC, Harries-Jones EP, Tobias R, et al. Prospective controlled trial of transhepatic biliary endoprosthesis versus biliary bypass surgery for incurable carcinoma of head of pancreas. Lancet 1986;1:69-71.
20. Bosset JF, Pavy JJ, Gillet M, et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer:results of a prospective study. Radiother Oncol 1992;24:191-4.
21. Boz G, DePaoli A, Roncadin M, et al. Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma. Tumori 1991;77:61-4.
22. Braasch JW, Deziel DJ, Rossi RL, et al. Pyloric and gastric preserving pancreatic resections:experience with 87 patients. Ann Surg 1986;204:411-8.
23. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreat 1997;21:1-12.
24. Bramhall SR, Allum AG, Jones AG, et al. Treatment and survival of 12560 patients with pancreatic cancer, and incidence of the disease, in the West midlands:an epidemiological study. Br J Surg 1995;82:111-5.
25. Bramhall SR, Neoptolemos JP. Adjuvant chemotherapy in pancreatic cancer. Int J Pancreatol 1997;21:59-63.
26. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma. Cancer 1998;83:2317-23.
27. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: de Vita V, Hellmann S, Rosenberg SA. Cancer principles and practice of oncology. Philadelphia: Lippincott, 1993:849-82.
28. Büchler MW, Wagner M, Friess H. Surgery for pancreatic cancer. In: Dervems CG. Advances in pancreatic disease. Stuttgart: Thieme, 1996:309-23.
29. Bukowski RM, Balcerak SP, O'Brian RM, et al. Randomized trial of 5-fluoruracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 1983;52:1577-82.
30. Burris H, Stornioli AM. Assessing clinical benefit in the treatment of pancreas cancer:gemcitabine compared to 5-fluoruracil. Eur J Cancer 1997;1:18-22.
31. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;6:2403-13.
32. Caldas C, Hahn SA, daCosta LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8: 27-32.
33. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-673.
34. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-5.
35. Caraceni AG, Portenoy RK. Pain management in patients with pancreatic carcinoma. Cancer 1996;Suppl:78: 639-53.
36. Carmichael J, Fink U, Russell RCG, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5.
37. Carter SK, Comis L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2:193-214.
38. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gremcitabine in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
39. Chlebowski RT, Bilcavage L, Grosvenor M, et al. Hydrazine sulfate in cancer patients with weight loss:a placebocontrolled clinical experience. Cancer 1987;59:406-10.
40. Citron ML, Kalra JM, Seltzer VL, et al. Patient-controlled analgesia for cancer pain:a long-term study of inpatient and outpatient use. Cancer Invest 1992;10:335-41.
41. Clark JW, Glicksman AS, Wanebo HJ. Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer 1996;Suppl 78:688-93.
42. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg 1996;223:271-9.
43. Crown J, Casper ES, Botet J, et al. Lack of efficacy of high-dose leucovorin and fluoruracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.
44. Cull AM Cancer-specific quality of life questionnaires:the state of the art in europe. Eur J Cancer 1997;33:Suppl 6:S3-7.
45. Cullinan S, Moertel CG, Wienand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluation of the Mallinson regimen and combined 5-fluoruracil, doxorubicin, and cisplatin. Cancer 1990;65: 2207-12.
46. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluoruracil vs fluoruracil and doxorubicin vs fluoruracil, doxorubicin and mitomycin. JAMA 1985;253:2061-7.
47. DeCaprio JA, Mayer RJ, Gonin R, et al. Fluoruracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas:results of a phase II trial. J Clin Oncol 1991;9:2128-33.
48. Deutsches Krebsforchungszentrum (DKFZ). Krebskalender 1997.
49. Dobelbower RR, Merrick HW, Khuder S, et al. Adjuvant radiation therapy for pancreatic cancer:A 15-year-experience. Int J Radiat Biol Phys 1997;39:31-7.
50. Downer S, Joel S, Albright A, et al. A double blind placebo controlled trial of medroxyprogesterone acetate for the treatmeut of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.
51. Dowsett JF, Russell RCG, Hatfield ARW, et al. Malignant obstructive jaundice: a prospective randomized trial of bypass-surgery versus endoscopic stenting. Gastroenterology 1989;96:128A.
52. Edge SB, Schmieg RE, Rosenhof LK, et al. Pancreas cancer resection outcome in American university centers in 1989-1990. Cancer 1993;71:3502-8.
53. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995;273: 1605-9.
54. Farrell TJ, Barbot DJ, Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann Surg 1997;226:66-9.
55. Fernandez E, LaVecchia CL, Porta M, et al. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995;11:185-9.
56. Fernandez-del Castillo C, Warshaw AL. Pancreatic carcinoma. Curr Opin Gastroenterol 1994;10:507-12.
57. Flanders TY, Foulkes WD. Pancreatic adenocarcinoma:epidemiology and genetics. J Med Genet 1996; 33:889-98.
58. Foley KM. Pain assessment of cancer pain syndromes. In: Doyle D, Hanks GW, MacDonald N. Oxford textbook of palliative medicine. Oxford: Oxford University Press 1993:148-65.
59. Folkman J. What is the evidence that tumours are angiogenesis dependent? Natl Cancer Inst 1990;82:4-6.
60. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Ann Surg 1984;199:418-25.
61. Fras J, Litin E, Pearson J. Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am J Psychiatry 1967;123:1553-62.
62. Friedman MA, Cassidy MJ, Hannigan JF, et al. A phase III study adriamycin + 5FU vs BCNU + adriamycm + ftorafur for patients with advanced pancreatic cancer. Proc Am Assoc Cancer Res and Am Soc Clin Oncol 1981; 22:156.
63. Friess H, Kleeff J, Gumbs A, et al. Molecular versus conventional markers in pancreatic cancer. Digestion 1997; 58:557-63.
64. Friess H, Yamanaka Y, Büchler MW, et al. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of the type III receptor. Cancer Res 1993;53:2704-7.
65. Fuchs CS, Colditz GA, Sampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1997;156:2250-60.
66. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of carcinoma of the pancreas. Cancer 1987;59:2006-10.
67. Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluoruracil plus doxorubicin plus initomycin C and two regimens of streptozotocin plus mitomycin plus fluoruracil. J Clin Oncol 1986;4:1794-8.
68. Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluoruracil for the treatment of locally unresectable cancer. Cancer 1985;56: 2563-8.
69. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas:comparison of combined modality treatment (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
70. Geer RF, Brennan MF. Prognostic indicators for survival after resection of pancreatic adeno carcinoma. Am J Surg 1993;165:68-73.
71. Ghadirian P, Howe GR. Nutrition, alcohol and coffee and cancer of the pancreas. Inst J Pancreatol 1994;16:204-7.
72. Glimelius B, Hoffmann K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
73. Goldstein AM, Fraser MC, Streuwing JP, et al. Increased risk of pancreatic cancel in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
74. Gordis L, Consumption of methylxanthine-containing beverages and risk of pancreatic cancer. Cancer Lett 1990; 52:1-12.
75. Grace PA, Pitt HA, Tompkins RK, et al. Decreased morbidity and mortality after pancreatectomy. Am J Surg 1986; 151:141-9.
76. Grace PA, Pitt HA, Longmire WP. Pancreatoduodenectomy with pylorus preservation for adenocarcinoma of the head of the pancreas. Br J Surg 1986;73:647-50.
77. Grahm AL, Andrén-Sandberg. A prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997; 58:542-9.
78. Green A, Austin C. Psychopathology of pancreatic cancer: A psychobiologic probe. Psychosomatics 1993;34: 202-21.
79. Griffin JF, Smalley R, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61.
80. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987;60:2284-303.
81. Gudjonsson B. Carcinoma of the pancreas: Critical analysis of costs, results of resections, and the need of standardized reporting. J Am Coll Surg 1995;181:483-503.
82. Gullo L, Pezzilli R, Morselli-Labate AM and the Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994;331:81-4.
83. Hahn SA, Kern SE,Schmiegel WH. Neue molekularbiologische Erkenntnisse aus der Pankreaskarzinom-Forschung. Dtsch Ärztebl 1997;94:3342-50.
84. Hahn SA, Schutte M, Hoque ATM, et al. DPC4, A candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;217:350-3.
85. Henne-Bruns D, Vogel I, Luttges J, et al. Ductal adenocarcinoma of the pancreas head:survival after regional versus extended lymphadenectomy. Hepatogastroenterology 1998;45:855-66.
86. Holland JC, Korzun A, Tross S, et al. Comparative psychological distrubance in patients with pancreatic and gastric cancer. Am J Psychiatry 1986;143:982-6.
87. Howe GR, Burch JD. Nutrition and pancreatic cancer. Cancer Causes Control 1996;7:69-82.
88. Hruban RH, van Mansfeld AD, Offerhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas:a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonuceotide hybridization. Am J Pathol 1993;143:545-5.
89. Huguier M, Samama G, Testart J, et al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Assiocation for Surgical Research. Am J Surg 1992;1264:348-53.
90. Inagaki J, Rodriguez V, Bodey GP. Proceedings: Causes of death in cancer patients. Cancer 1974;33:568-73.
91. Jeekel J, Treurniet-Donker AD. Treatment perspectives in locally advanced unresectable pancreatic cancer. Br J Surg 1991;78:1332-4.
92. Joffe R, Rubinow D, Demicoff K, et al. Depression and carcinoma of the pancreas. Gen Hosp Psychiatry 1986; 8:241-5.
93. Kalser MH, Ellengerg SS, Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
94. Karlson BM, Ekbom A, Josefsson S, et al The risk of pancreatic cancer following pancreatitis: an association due to confounding? Gastroenterology 1996;113:587-92.
95. Keating JJ, Johnson PJ, Cochrane AM, et al. A prospecteronacetate in pancreatic carcinoma. Br J Cancer 1989;69:789-92.
96. Kelsen D, Hudis C, Niedzwiecki D, et al. A phase III comparison of streptozotocin, mitomycin, and 5-fluoruracil with cisplatin, cytosin arabinoside and caffein in patients with advanced pancreation cancer. Cancer 1991; 68: 965-9.
97. Kelsen D, Portenoy R. Thaler H, et al. Pain and depression in patients with newly diagnosed pancreatic cancer. J Clin Oncol 1995;13;7-8-55.
98. Kinsella TJ, Sindelar WT. Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies. Cancer 1996; 78;Suppl 3:598-604.
99. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas:a randomized comparison of 5-fluoruracil alone with radiation plus concurrent and maintenance 5-fluoruracil. An Eastern Cooperative Oncology Group Study. J Clin Onco 1985;3:373-8.
100. Klöppel G, Solcia E, Longnecker DS, et al., eds. WHO: International histological classification of tumours: Histological typing of tumours of the exocrine pancreas. Berlin: Springer, 1996.
101. Korc M, Chandrasekar, B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the level of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90: 1352-60.
102. Lebowits AH, Lefkowitz M. Pain management of pancreatic carcinoma: a review. Pain 1989;36:1-11.
103. Lemoine NR. Molecular advances in pancreatic cancer. Digestion 1997;58:550-6.
104. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg 1995;221:133-48.
105. Lillemoe KD, Cameron JL, Kaufmann HS, et al. Chemical splanchnectomy in patients with unresectable pancreatic cancer:a prospective randomized trial. Ann Surg 1993;217:447-57.
106. Lillemoe KD, Pitt HA. Palliation - surgical and otherwise. Cancer 1996;78:Suppl 3:609-14.
107. Lionetto R, Pugliese V. Bruzzi P, et al. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995;31:882-7.
108. Loprinzi CL, Schaid DH, Dose AM, et al. Body-composition changes in patients who gain weight while receiving megestrol acetat. J Clin Oncol 1993;11:15-4.
109. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
110. Lowenfels AB, Maissonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997;89:442-6.
111. Lynch AT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: A review. Semin Oncol 1996;23:251-75.
112. Lynch HT, Fiotzsimmons ML, Smyrk, TC, et al. Familial pancreatic carcinoma: clinicopathologic study of 128 nuclear families. Am J Gastroenterol 1990;85:54-60.
113. Mack TM, Yu MC, Hanisch R, et al. Pancreas cancer and smoking, beverage consumption and past medical history. J Natl Cancer hist 1986;76:49-60.
114. Mallinson CN, Rake MO, Cocking JB. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomized multicentre trial. Br Med J 1980;281: 1589-91.
115. Mancuso T, El-Attar A. Cohort study of workers exposed to betanaphthylamine and benzidine. J Occup Med 1967;9:277-85.
116. McGeer AJ, Detsky AS, O'Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 1996;6:233-40.
117. McGrath PC, Sloan DA, Kenady DE. Surgical management of pancreatic carcinoma. Semin Oncol 1996;23: 200-12.
118. Mercadante S. Celiac plexus block versus analgesics in pancreatic cancer pain. Pain 1993;52:187-92.
119. Moertel CG, Frytag S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma:A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluoruracil), and high dose radiation + 5-fluoruracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
120. Mohiuddin M, Regine WF, Stevens J, et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995;13:2764-8.
121. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 1996;78:Suppl 3:633-7.
122. Moulin DE, Kreeft JH, Murray PN, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991;337:465-8.
123. Muscat JE, Stellmann SD, Hoffmann D, et al. Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomarkers Prev 1997;6:15-9.
124. Neoptolemos JP, Kerr DJ, Beger H, et al. ESPAC-1 Trial Progress Report: The European Randomized Adjuvant Study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997;58:570-7.
125. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiation Biol Phys 1997;39:39-49.
126. Noble S, Goa KL, Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54:447-72.
127. Offerhaus GJ, Tersmette AC, Tersmette KW, et al. Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Review of the literature with the emphasis on risk assessment and underlying mechanism. Mod Pathol 1988;1:352-6.
128. Oken MM, Creech RH, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:549-55.
129. Oster MW, Gray R, Panasci L, et al., for Cancer and Leukemia Group B, Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluoruracil, adriamycin and mitomycin (FAM) with 5-fluoruracil, streptozotocin and mitomycin (FSM) Cancer 1986;57:29-33.
130. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-5.
131. Passik SD, Breitbart WS. Depression in patients with pancreatic carcioma. Cancer 1996;78:Suppl 3:615-25.
132. Patel AG, Toyama MT, Kusske AM, et al. Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg 1995;130:838-42.
133. Pazdur R, Ajani JJ, Abbruzzese JL, et al. Phase II evaluation of fluoruracil and recombinant alpha-2b-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992;70:2073-6.
134. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of pancreatic head cancer. A multicenter prospective randomized study. Lymphadenectomy study group. Ann Surg 1998;228:508-17.
135. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and non-ductal tumours progress through different genetic lesions. Cancer Res 1994;54:1556-60.
136. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994;330:313-8.
137. Pluda JM, Parkinson DR. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 1996;78:680-7.
138. Prott FJ, Schönekaes K, Preusser P, et al. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas:results of a feasibility study. Br J Cancer 1997;75:597-601.
139. Roder, JD, Stein HJ, Huttl W, et al. Pylorus-preserving versus standard pancreatico-duodenectomyian analysis of 110 pancreatic and periampullary carcinomas. Br J Surg 1992;79:152-5.
140. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;359:485-9.
141. Rosewicz S, Stier U, Brembeck F, et al. Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology 1995;109:1646-60.
142. Ross AH, Smith MA, Anderson JR, et al. Late mortality after surgery for peptic ulcer. N Engl J Med 1982;307:519-22.
143. Rosvold E, Schilder RJ, Walczak J. Phase II trial of PALA in combination with 5-fluoruracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 1992;29: 305-8.
144. Rothenberg ML, Abbruzzese JL, Moore M, et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996;67: 627-32.
145. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
146. Rothmann H, Cantrell JE, Lokich J, et al. Continuous infusion of 5-fluouracil plus weekly cisplatin for pancreatic carcinoma:A Mid-Atlantic Oncology Program Study. Cancer 1991;68:264-8.
147. Saltzburg D, Foley KM, Management of pain in pancreatic cancer. Surg Clin North Am 1989;69:629-49.
148. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
149. Schein PS, Lavin PT, Moertel CG, et al. Randomized phase II clinical trial of adriamycin, methotrexate and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group report. Cancer 1978;42:19-22.
150. Schmiegel W, Schmielau J, Henne-Bruns D, et al. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to therapy of pancreatic cancer. Proc Natl Acad Sci USA 1997;94:12622-6.
151. Schnall SF, Macdonald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996;23:220-8.
152. Seydel G, Stablein DM, Leichman LP, et al. Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. Cancer 1990;65:1478-82.
153. Shepherd HA, Royle G, Ross APR, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct:a randomized trial. Br J Surg 1988;75:1166-8.
154. Silverman DT, Dunn JA, Hoover, RN, et al. Cigarette smoking and pancreas cancer:a case-control study based on direct interviews. J Natl Cancer Inst 1994;86:1510-6.
155. Sindelar WF, Kinsella TJ. Randomized trial of intraoperative radiotherapy in resected carcinoma of the pancreas. Int J Radiat Biol Phys 1986;12:148-52.
156. Smith FP, Hoth DF, Levin B, et al. 5-fluoruracil, adriamycin and mitomycin C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980;46:2014-8.
157. Smith FP, Stablein DM, Schein PS, for the Gastrointestinal Tumor Study Group (GITSG). Phase II combination chemotherapy trials in advanced measurable pancreatic cancer. Proc Am Soc Clin Oncol 1982;3: 150-5.
158. Sobin LK, Wittekind C, eds. UICC International Union Against Cancer. TNM classification of malignant tumours, 5th edn. New York: Wiley-Liss, 1997:87-90.
159. Speer AG, Cotton PB, Russel, RCG, et al. Randomized trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987;2:57-62.
160. Sperti C, Pasquali C, Catalini S, et al. Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin). Eur J Surg Oncol 1992;18:267-71.
161. Taylor OM, Benson EA, McMahon MJ, and the Yorkshire Gastrointestinal Tumour Group. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg 1993;80:384-6.
162. Thomas PRM. Radiotherapy for carcinoma of the pancreas. Semin Oncol 1996;23:213-9.
163. Tian E, Ardalan B, Benedetto P, et al. A phase II study of short term protracted infusion of high dose 5-fluoruracil (5-FU) with leucovorin (LV) and low-dose phophonoacetyl-L-aspartic acid (PALA) in pancreatic carcinoma. Proc Am Soc Clin Oncol 1992;111:184-8.
164. Tisdale MJ. Biology of cachexia (review). J Natl Cancer Inst 1997;89:1763-77.
165. Traverso LW, Longmire WP. Preservation of the pylorus in pancreaticoduodenctomy. Surg Gynaecol Obstet 1978;146:959-62.
166. Trede T, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. Ann Surg 1990;211:447-58.
167. US Department of Health and Human Services, Public Health Services, Agency für Health Care Policy and Research. Management of cancer pain: Clinical practice guideline Number 9. AHCPR Publication No. 94-0592, 1994.
168. van Heerden JA, ReMine WH, Weiland LH, et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas. Mayo Clinic experience. Am J Surg 1981;142:309-11.
169. Wagener DJT, Hoesel QGCM, VanYap SH, Phase II trial of 5-FU in locally advanced pancreatic cancer. Cancer Chemother Pharmacol 1989;25:131-4.
170. Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78:Suppl 3:580-91.
171. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
172. Watanapa P, Williamson RCN. Surgical palliation for pancreatic cancer:developments during the past two decades. Br J Surg 1992;79:8-20.
173. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-7.
174. Whittington R, Neuberg D, Tester WJ, et al. Protracted intravenous fluoruracil infusion with radiation therapy in the management of localized pancreaticobiliary cancer;a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995;13:227-32.
175. Wigmore SJ, Plester CE, Richardson RA, et al. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997;75:106-9.
176. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996;12:27-30.
177. Wils J, Bleiberg H, Blijham G, et al. Phase-II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985;21:191-4.
178. World Health Organization. Cancer pain relief and palliative care, 2nd edn. Geneva: World Health Organization. 1990.
179. Yamanaka Y, Friess H, Buchler HW, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced cancer stage. Cancer Res 1993;53:5289-96.
180. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-70.
181. Yasue M, Sakamoto J, Kasui K, et al. A randomized trial of intraoperative radiation therapy (IORT) vs IORT plus chemotherapy (MTX-5-FU) for adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 1992;11: 161-8.
182. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. Ann Surg 1995;221:721-33.
183. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticduodenectomy for pancreatic adenocarcionma: postoperative adjuvant chemoradiaton improves survival. A prospective single-institution experience. Ann Surg 1997;225 621-33.
184. Zerbi A, Fossati V, Parolini D, et al. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994;73:2930-5.